HC Wainwright Boosts Earnings Estimates for Biomea Fusion

Biomea Fusion, Inc. (NASDAQ:BMEAFree Report) – Research analysts at HC Wainwright raised their Q2 2025 earnings estimates for shares of Biomea Fusion in a research note issued to investors on Monday, June 23rd. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.46) per share for the quarter, up from their previous estimate of ($0.66). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion’s Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.92) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.14) EPS and FY2028 earnings at ($2.27) EPS.

Biomea Fusion (NASDAQ:BMEAGet Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.04.

A number of other brokerages also recently issued reports on BMEA. Barclays cut their price objective on Biomea Fusion from $11.00 to $3.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 2nd. D. Boral Capital reissued a “buy” rating and set a $16.00 price objective on shares of Biomea Fusion in a research report on Tuesday. Oppenheimer set a $10.00 price objective on Biomea Fusion in a research report on Monday, March 24th. Finally, Piper Sandler began coverage on Biomea Fusion in a research report on Tuesday, June 3rd. They issued an “overweight” rating and a $7.00 target price for the company. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $21.40.

Get Our Latest Stock Analysis on BMEA

Biomea Fusion Stock Down 9.0%

Shares of BMEA opened at $1.81 on Thursday. Biomea Fusion has a 52-week low of $1.29 and a 52-week high of $13.07. The company has a market capitalization of $68.00 million, a PE ratio of -0.51 and a beta of -0.23. The stock has a fifty day simple moving average of $1.94 and a two-hundred day simple moving average of $2.86.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in BMEA. CWM LLC raised its stake in Biomea Fusion by 8,058.5% during the 1st quarter. CWM LLC now owns 16,888 shares of the company’s stock valued at $36,000 after acquiring an additional 16,681 shares in the last quarter. Cerity Partners LLC bought a new stake in Biomea Fusion during the 1st quarter valued at $37,000. Bayesian Capital Management LP bought a new stake in Biomea Fusion during the 4th quarter valued at $42,000. Wells Fargo & Company MN raised its stake in Biomea Fusion by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 12,914 shares of the company’s stock valued at $50,000 after acquiring an additional 4,399 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in Biomea Fusion during the 4th quarter valued at $54,000. Institutional investors and hedge funds own 96.72% of the company’s stock.

About Biomea Fusion

(Get Free Report)

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.

Read More

Earnings History and Estimates for Biomea Fusion (NASDAQ:BMEA)

Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.